Leyns, Cheryl E. G. http://orcid.org/0000-0001-5513-7758
Gratuze, Maud
Narasimhan, Sneha
Jain, Nimansha
Koscal, Lauren J.
Jiang, Hong
Manis, Melissa http://orcid.org/0000-0001-7912-2016
Colonna, Marco
Lee, Virginia M. Y.
Ulrich, Jason D. http://orcid.org/0000-0002-4743-926X
Holtzman, David M. http://orcid.org/0000-0002-3400-0856
Article History
Received: 1 March 2019
Accepted: 21 May 2019
First Online: 24 June 2019
Competing interests
: D.M.H., J.D.U., and H.J. are listed as inventors on a provisional patent from Washington University on TREM2 antibodies. D.M.H., H.J., and C.E.G.L. are listed as inventors on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. C.E.G.L. is currently an employee at Merck. M.C. receives research funding from Alector, Amgen, and Ono. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. C2N Diagnostics has licensed certain anti-tau antibodies to AbbVie for therapeutic development. D.M.H. is on the scientific advisory board of Proclara and Denali and consults for Genentech, Eli Lilly, and AbbVie. All other authors have no competing interests.